EUVIMEDEUVIMED entdecken
Crossref

Investigating Novel Biomarkers and Therapeutic Targets for Liver Regeneration

Benjamin K. Chan

University of Liverpool · 01.01.2028

DOI: 10.17638/03184183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift University of Liverpool, erschienen am 01.01.2028. Verfasst von Benjamin K. Chan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Liver surgery remains the mainstay cure for cancer patients. However, this requires a sufficient future liver remnant (FLR >25%) or risks post-hepatectomy liver failure (PHLF; 10% incidence) from inadequate liver function. The transcription factor Nuclear factor erythroid 2-related factor 2 (Nrf2) regulates metabolic and cellular defences. Emerging evidence supports Nrf2 activation as therapeutic applications in oxidative/inflammatory diseases. The hepatokine Fibroblast growth factor 21 (FGF21) is a metabolic regulator. Several pharmaceutical companies are developing FGF21 modulators as treatments for metabolic/liver diseases.

Aims

To understand mechanisms of liver regeneration amenable to pharmacological enhancement via antioxidative and metabolic adaptations to reduce PHLF.

Results

CDDO-Me (Nrf2 activator) enhanced the rate of restoration of liver mass (liver / body mass ratio), volume (MRI) and stabilized function (serum markers) in (C57BL/6) mice post-hepatectomy. These effects were associated with hepatocyte hypertrophy (cytometry) and metabolic adaptation (RNA-Seq) via Nrf2 in the liver remnant, with no disconcerting morphological differences (histology) or neoplastic signal (RNA-Seq). Liver FGF21 (qPCR) was up-regulated post-hepatectomy and enhanced by CDDO-Me and correlated with serum FGF21 (ELISA). Whilst CDDO-Me enhanced regeneration was validated in (129/SvEv-C57BL/6) mice, this was independent of FGF21 (FGF21 knockout mice). However, LY2405319 (FGF21 analogue) enhanced regeneration (liver / body mass ratio and MRI) in mice post-hepatectomy. Lastly, in a cohort of 155 patients, serum FGF21 (ELISA) dynamics were associated with liver regeneration, diagnostic of PHLF, and prognostic of post-hepatectomy outcomes.

Conclusions

Pre-clinically pharmacological activation of Nrf2 and FGF21 enhanced liver regeneration, whilst serum FGF21 dynamics was a clinically relevant regenerative biomarker.

Schlagwörter

liver regenerationpost-hepatectomy liver failureNrf2bardoxolone methylFGF21hepatocyte hypertrophymetabolic adaptationoxidative stressprognostic factorsliver cancer surgery

Zitieren

APA

Chan, B. K. (2028). Investigating Novel Biomarkers and Therapeutic Targets for Liver Regeneration. University of Liverpool. https://doi.org/10.17638/03184183

Vancouver

Chan BK. Investigating Novel Biomarkers and Therapeutic Targets for Liver Regeneration. University of Liverpool. 2028. doi:10.17638/03184183

BibTeX
@article{Chan2028,
  author = {Chan, Benjamin K.},
  title = {Investigating Novel Biomarkers and Therapeutic Targets for Liver Regeneration},
  journal = {University of Liverpool},
  year = {2028},
  doi = {10.17638/03184183}
}
Kostenlos starten →